Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Product Surveillance, Postmarketing | 2 | 2013 | 38 | 0.850 |
Why?
|
| Medical Records | 2 | 2013 | 120 | 0.810 |
Why?
|
| Rotavirus Vaccines | 2 | 2013 | 8 | 0.530 |
Why?
|
| Consumer Product Safety | 1 | 2013 | 11 | 0.430 |
Why?
|
| Uncertainty | 1 | 2013 | 76 | 0.410 |
Why?
|
| Patient Safety | 1 | 2013 | 217 | 0.350 |
Why?
|
| Models, Statistical | 1 | 2013 | 576 | 0.330 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 846 | 0.320 |
Why?
|
| Vaccines, Attenuated | 2 | 2013 | 52 | 0.210 |
Why?
|
| Acute Kidney Injury | 2 | 2015 | 317 | 0.180 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 204 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 2 | 2015 | 1063 | 0.140 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 91 | 0.120 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 419 | 0.120 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2016 | 175 | 0.120 |
Why?
|
| Adenine Nucleotides | 1 | 2014 | 63 | 0.120 |
Why?
|
| Arabinonucleosides | 1 | 2014 | 39 | 0.120 |
Why?
|
| Food Contamination | 1 | 2013 | 32 | 0.110 |
Why?
|
| Mass Screening | 1 | 2018 | 642 | 0.110 |
Why?
|
| Cisplatin | 1 | 2016 | 618 | 0.110 |
Why?
|
| Oryza | 1 | 2013 | 42 | 0.110 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 349 | 0.110 |
Why?
|
| Normal Distribution | 1 | 2013 | 38 | 0.110 |
Why?
|
| Intussusception | 1 | 2013 | 18 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 243 | 0.100 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 309 | 0.100 |
Why?
|
| Carcinoma, Papillary | 1 | 2013 | 160 | 0.100 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 374 | 0.100 |
Why?
|
| Environmental Exposure | 1 | 2013 | 330 | 0.090 |
Why?
|
| Arsenic | 1 | 2013 | 260 | 0.090 |
Why?
|
| Carcinoma | 1 | 2013 | 443 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2013 | 426 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2411 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 891 | 0.070 |
Why?
|
| Graft vs Host Reaction | 1 | 2006 | 15 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 1099 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3473 | 0.070 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2006 | 91 | 0.070 |
Why?
|
| RNA Editing | 1 | 2006 | 35 | 0.070 |
Why?
|
| Infant | 1 | 2013 | 3171 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2006 | 268 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2416 | 0.060 |
Why?
|
| Kidney Function Tests | 2 | 2015 | 115 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 3019 | 0.060 |
Why?
|
| Humans | 9 | 2018 | 89760 | 0.060 |
Why?
|
| Middle Aged | 7 | 2018 | 26129 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 2025 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 1218 | 0.050 |
Why?
|
| Adult | 5 | 2018 | 26742 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2016 | 8283 | 0.040 |
Why?
|
| Female | 6 | 2018 | 46439 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2015 | 2882 | 0.040 |
Why?
|
| Aged | 4 | 2016 | 19280 | 0.040 |
Why?
|
| Pharmacogenomic Variants | 1 | 2016 | 42 | 0.030 |
Why?
|
| Mammography | 1 | 2018 | 474 | 0.030 |
Why?
|
| Male | 5 | 2016 | 42632 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1185 | 0.030 |
Why?
|
| Creatinine | 1 | 2015 | 294 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 337 | 0.030 |
Why?
|
| Dermatitis | 1 | 2013 | 34 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 181 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2014 | 156 | 0.030 |
Why?
|
| Weight Loss | 1 | 2015 | 229 | 0.030 |
Why?
|
| Risk Factors | 2 | 2014 | 5522 | 0.030 |
Why?
|
| Drinking Water | 1 | 2013 | 64 | 0.030 |
Why?
|
| Bangladesh | 1 | 2013 | 331 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 378 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1535 | 0.030 |
Why?
|
| Skin Diseases | 1 | 2013 | 173 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 684 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2014 | 997 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 503 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2013 | 334 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 864 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 988 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 343 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2015 | 9100 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 1078 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 4328 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 1246 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 2355 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 1599 | 0.020 |
Why?
|
| Chicago | 1 | 2013 | 1436 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1848 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1370 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 4167 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 3672 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 3802 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 6847 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 5346 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2006 | 950 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 1577 | 0.010 |
Why?
|
| Young Adult | 1 | 2013 | 6360 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 9295 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 3229 | 0.010 |
Why?
|
| Mice | 1 | 2006 | 11814 | 0.010 |
Why?
|
| Animals | 1 | 2006 | 27456 | 0.000 |
Why?
|